Abstract
Controlling spread of disease due to infectious agents require a quick response from public health sector. In the ongoing COVID-19 pandemic, the use of antigen tests has shown to be an excellent tool to inform authorities and mitigate the spread of the disease. In this communication we demonstrated how performance of an antigen test -- as a diagnostic in vitro device -- can be properly validated using quantitative laboratory experimentation and self-testing data from a clinical study. We also show how clinical performance of an antigen test can be predicted using mathematical modeling. The proposed appraisal methodology of antigen test performance under real-world conditions could be a useful tool to inform regulatory decision making. This approach allows to standardize, democratize, and speed up the process of validation, analysis, and comparison of antigen rapid tests, and thus to help developing effective public health response strategies.
Competing Interest Statement
Irene Bosch is the founder and owner of IDX20, a company affiliated with this study. Miguel Bosch is the founder and owner of Info Analytics Innovations, a company also affiliated with this study. The authors declare no additional conflicts of interest.
Funding Statement
This research was supported by Reagan-Udall Foundation through Grant #02282022 RUF, awarded to IDX20.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Advarra gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data is available at the Rapid Acceleration of Diagnostics - Underserved Populations (RADxUP, a program funded by the National Institutes of Health (NIH), under the repository conditions.
